Opinion|Videos|August 12, 2024
Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd
Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.
Advertisement
Episodes in this series
- How do the toxicities of Dato-DXd, sacituzumabgovitecan and HER3-DXd compare? How are you managing these in your clinical practice?
- Hayashi et al. ELCC 2024. HER3-DXd in previously treated patients with advanced EGFR mutated NSCLC: Updated safety results from HERTHENA-Lung01
- Sands et al. ASCO 2024. Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd).
Advertisement
Related to this article
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.
Faculty members gathered at an OncLive Scientific Interchange and Workshop to discuss individualizing care in EGFR-mutated NSCLC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
4
Dive Into Key Data and Presentations From EHA 2026
5